Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
Journal of Virology|October 28, 2004
Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivityNicole G Newcombe, Leone G Beagley, Dale Christiansen, et al.CPT: Pharmacometrics & Systems Pharmacology|February 18, 2020
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology ModelingVictor Sokolov, Tatiana Yakovleva, Lulu Chu, et al.Clinical Pharmacology in Drug Development|September 23, 2016
Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate BindersSusanne Johansson, Maria Leonsson-Zachrisson, Mikael Knutsson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21Darren R Shafren, Gough G Au, Tam Nguyen, et al.Scientific Reports|October 25, 2024
Field and laboratory perspectives on fentanyl and carfentanil decontaminationPernilla Lindén, Lina Mörén, Johanna Qvarnström, et al.Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 13, 2011
Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenouslyAladár Rónaszéki, Marco Alings, Kenneth Egstrup, et al.Journal of Cardiovascular Pharmacology|July 1, 2010
A randomized invasive cardiac electrophysiology study of the combined ion channel blocker AZD1305 in patients after catheter ablation of atrial flutterLauri Toivonen, Pekka Raatikainen, Håkan Walfridsson, et al.Diabetes, Obesity & Metabolism|August 20, 2019
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitorsTatiana Yakovleva, Victor Sokolov, Lulu Chu, et al.Clinical and Translational Science|August 16, 2022
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trialIain B Squire, Anders Gabrielsen, Peter J Greasley, et al.British Journal of Clinical Pharmacology|February 18, 2025
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenoneChandrali S Bhattacharya, Hans Ericsson, Susanne Johansson, et al.Pageof 7